CliffBio
biologic

Rituxan Hycela

rituximab and hyaluronidase human

Loss of exclusivityJune 2029projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameRituxan Hycela
Active ingredientrituximab and hyaluronidase human
Strength1,600MG/13.4ML; 26,800UNITS/13.4ML (120MG/2,000UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2017
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.